Clinical Trials Logo

Thalidomide clinical trials

View clinical trials related to Thalidomide.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06268093 Recruiting - Syringomyelia Clinical Trials

The Therapeutic Effect of Thalidomide in Syringomyelia

Start date: February 2024
Phase: Phase 2
Study type: Interventional

Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia. Primary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.

NCT ID: NCT06256627 Recruiting - Clinical trials for Acute Myeloid Leukemia

The Maintenance Treatment of "ITIVA" in AML Patients

Start date: July 11, 2023
Phase: N/A
Study type: Interventional

We apply for this clinical study to evaluate the efficacy of "combined recombinant human interference'- α- 1b, interleukin-2, and thalidomide" regimen in obtaining MRD positive AML patients in CR,as well as the efficacy of the "Venentoclax and azacitidine" regimen and the "combined recombinant human interference'- α- 1b, interleukin-2, and thalidomide" regimen in alternately maintaining the treatment of MRD negative AML patients. The study included two cohorts. The first cohort consisted of AML patients who obtained CR or CRi but MRD positive after induction chemotherapy and consolidation chemotherapy. They were randomly given two cycles of "recombinant human interference'- α- 1b, interleukin-2, and thalidomide" or "VA" regimen treatment, and the MRD conversion rates of the two groups were analyzed. In the second cohort , after induction chemotherapy and consolidation chemotherapy, AML patients with CR or CRi and negative MRD were obtained, and were given "recombinant human interference'- α- 1b, interleukin-2, and thalidomide", Venentoclax and Azacitidine triple alternative maintenance treatment, to analyze the impact of maintenance treatment scheme on long-term survival of aml patients.

NCT ID: NCT03318835 Recruiting - Thalidomide Clinical Trials

Thalidomide Combined With R-CHOP in Newly Diagnosed,Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients

Start date: August 22, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Thalidomide combined with R-CHOP(RT-CHOP) in newly diagnosed,untreated double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL)